NYSE:IMAX • CA45245E1097
ChartMill assigns a Buy % Consensus number of 82% to IMAX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-24 | Rosenblatt | Maintains | Buy -> Buy |
| 2026-02-23 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-01-26 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-01-15 | Macquarie | Maintains | Outperform -> Outperform |
| 2025-12-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-15 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-12-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-12-08 | Benchmark | Maintains | Buy -> Buy |
| 2025-12-08 | Rosenblatt | Maintains | Buy -> Buy |
| 2025-12-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-11-25 | Goldman Sachs | Upgrade | Sell -> Neutral |
| 2025-10-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-24 | Rosenblatt | Maintains | Buy -> Buy |
| 2025-10-24 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-24 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-10-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-14 | Roth Capital | Maintains | Buy -> Buy |
| 2025-10-09 | Rosenblatt | Maintains | Buy -> Buy |
| 2025-10-09 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-09-22 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-19 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-07-25 | Benchmark | Maintains | Buy -> Buy |
| 2025-07-25 | Rosenblatt | Maintains | Buy -> Buy |
| 2025-07-25 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-07-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-07-11 | Rosenblatt | Maintains | Buy -> Buy |
| 2025-07-09 | Roth Capital | Reiterate | Buy -> Buy |
| 2025-06-16 | Rosenblatt | Maintains | Buy -> Buy |
18 analysts have analysed IMAX and the average price target is 45.22 USD. This implies a price increase of 22.78% is expected in the next year compared to the current price of 36.83.
The consensus rating for IMAX CORP (IMAX) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering IMAX CORP (IMAX) is 18.